Home / Healthcare/ Bristol-Myers beefs up cancer portfolio with $ 74 b Celgene buy

Bristol-Myers beefs up cancer portfolio with $ 74 b Celgene buy


Comments / {{hitsCtrl.values.hits}} Views / Monday, 7 January 2019 00:34

Facebook

FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at building in Le Passage, near Agen, France - Reuters

REUTERS: Bristol-Myers Squibb Co said yesterday it would buy Celgene Corp for about $ 74 billion, creating a pharma company with several blockbuster cancer drugs and making it one of the biggest mergers on record in the 

sector. 

Bristol-Myers pioneered cancer immunotherapy with its Yervoy and later Opdivo, but has come under pressure as Merck & Co’s rival treatment Keytruda moved ahead in market share in lung cancer treatment, the most lucrative oncology market. 

The deal will create a company with nine treatments bringing in more than $ 1 billion in annual sales and a significant potential for growth in oncology, immunology and inflammation and cardiovascular disease. 

Celgene shareholders will receive one Bristol-Myers Squibb share and $ 50 in cash for each share held, or $ 102.43 per share, a premium of 53.7% to Celgene’s Wednesday close. 

Bristol-Myers shares fell 13% at $ 45.20, while Celgene shares rose 30.5% at $ 87 in premarket trading. 

Celgene shareholders will also receive one tradable contingent value right for each share held which will entitle them to receive a one-time potential payment of $ 9 in cash upon regulatory approval of ozanimod and liso-cel by 31 December 2020 and bb2121 by 31 March 2021. 

Talks opened in September, with Bristol-Myers approaching Celgene, according to a source familiar with the 

matter. 

Last year, Celgene bought experimental cancer drug developer Juno Therapeutics for $ 9 billion, betting on its chimeric antigen receptor T-cell therapy, known as 

CAR-T. 

Bristol-Myers said it expects to speed up a share repurchase program of up to about $ 5 billion, subject to the closing of the transaction, market conditions and board approval. 

The companies expect to close the deal in the third quarter of 2019. The cash portion will be funded through a combination of cash on hand and debt financing. 

Bristol-Myers Squibb has obtained fully committed debt financing from Morgan Stanley Senior Funding Inc and MUFG Bank Ltd. 

Morgan Stanley & Co. LLC is the lead financial adviser to Bristol-Myers, and Evercore and Dyal Co. LLC are its financial advisers. Kirkland & Ellis LLP is its legal counsel. 

J.P. Morgan Securities LLC is serving as lead financial adviser and Citi is the financial adviser to Celgene. Wachtell, Lipton, Rosen & Katz is its legal counsel.


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Those who go by social proof are easy prey to crafty schemers

Monday, 17 June 2019

Going after social proof Swiss writer and novelist, Rolf Dobelli, in one of the essays in his 2013 book ‘The Art of Thinking Clearly’, has given a fine warning to his readers. He has warned against going by ‘social proof’ or ‘majority view


Poson ponderings on positional power: ‘Authority vested’ vs. ‘authority wasted’

Monday, 17 June 2019

We witnessed a serene Poson Poya, in a far more improved security setting in Sri Lanka. Whilst the Sri Lankan life slowly returning to normal, political fronts do not appear to show the same. Has the political power become the people ‘pava’ (sin)


Emperors without clothes: Is Mother Lanka naked too?

Monday, 17 June 2019

The expression ‘The Emperor without clothes’ derives from the Hans Anderson tale that is based on Sufi wisdom. The Emperor in Anderson’s story was without doubt, the finest dressed man in the land and he loved wearing fine clothes and spent al


The confusion of the collision is becoming indescribable!

Monday, 17 June 2019

Strange are the things we are witnessing in the political scene. The fast-evaporating trust and confidence in politicians and the Government are seriously destroying the harmony of the nation. The Prime Minister of the country has admitted that the


Columnists More